非霍奇金淋巴瘤

预约门诊

生存率

非霍奇金淋巴瘤的生存率因人而异。影响因素包括非霍奇金淋巴瘤的类型、患者整体健康状况、癌症分期及所接受的治疗。为了解非霍奇金淋巴瘤的生存率，专家研究了大量非霍奇金淋巴瘤患者，以了解确诊后 5 年生存人数比例。

1 期非霍奇金淋巴瘤患者存活至少 5 年的几率约为 88%。随着癌症扩散，生存率会逐渐降低。4 期非霍奇金淋巴瘤患者存活至少 5 年的几率约为 64%。

生存率因非霍奇金淋巴瘤类型而异。弥漫性大 B 细胞淋巴瘤是最常见的非霍奇金淋巴瘤类型。此类型具有侵袭性，因此生存率通常相对较低。1 期患者存活至少 5 年的几率为 80%。4 期弥漫性大 B 细胞淋巴瘤患者生存至少 5 年的几率约为 55%。

滤泡性淋巴瘤是另一种常见的非霍奇金淋巴瘤。此类型属于惰性淋巴瘤，生长速度缓慢。生存率通常较高。1 期滤泡性淋巴瘤患者存活至少 5 年的几率约为 97%。4 期滤泡性淋巴瘤患者存活至少 5 年的几率约为 83%。

请注意，生存率统计数据需要 5 年才能采集到。最新生存率数据包含 5 年前接受过非霍奇金淋巴瘤治疗的患者。这些患者可能未接受过最新疗法。在过去数十年间，非霍奇金淋巴瘤死亡率持续下降，生存率稳步提升。

申请预约
分期医生与科室
Nov. 07, 2025

Living with 非霍奇金淋巴瘤?

Connect with others like you for support and answers to your questions in the Blood Cancers & Disorders support group on Mayo Clinic Connect, a patient community.

Blood Cancers & Disorders Discussions

mjlandin
Does anyone else have MGUS?

1135 Replies Sat, Jan 31, 2026

lindagi
AML successful treatment

75 Replies Sat, Jan 31, 2026

jak2mpnpositive
I have JAK2 ET and MPN: Anyone else have these symptoms?

111 Replies Sat, Jan 31, 2026

See more discussions
  1. B-cell lymphomas. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1480. Accessed Aug. 30, 2024.
  2. T-cell lymphomas. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1483. Accessed Aug. 30, 2024.
  3. Non-Hodgkin lymphoma (NHL). Leukemia & Lymphoma Society. https://www.lls.org/lymphoma/non-hodgkin-lymphoma. Accessed Sept. 16, 2024.
  4. DeVita VT Jr, et al., eds. Non-Hodgkin lymphoma. In: DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 12th ed. Wolters Kluwer; 2023. Accessed Aug. 28, 2024.
  5. Distress management. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1431. Accessed Aug. 29, 2024.
  6. Member institutions. Alliance for Clinical Trials in Oncology. https://www.allianceforclinicaltrialsinoncology.org/main/public/standard.xhtml?path=%2FPublic%2FInstitutions. Accessed Sept. 17, 2024.
  7. Member institution lists. NRG Oncology. https://www.nrgoncology.org/About-Us/Membership/Member-Institution-Lists. Accessed Sept. 17, 2024.
  8. Bock AM, et al. Bispecific antibodies for non-Hodgkin lymphoma treatment. Current Treatment Options in Oncology. 2022; doi:10.1007/s11864-021-00925-1.
  9. Tun AM, et al. Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies. Cancer Treatment Reviews. 2020; doi:10.1016/j.ctrv.2020.102042.
  10. Nowakowski GS, et al. Integrating precision medicine through evaluation of cell of origin treatment planning for diffuse large B-cell lymphoma. Blood Cancer Journal. 2019; doi:10.1038/s41408-019-0208-6.
  11. Laurent C, et al. Impact of expert pathologic review of lymphoma diagnosis: Study of patients from the French Lymphopath Network. Journal of Clinical Oncology. 2017; doi:10.1200/JCO.2016.71.2083.
  12. Paulson CL. Allscripts EPSi. Mayo Clinic. July 15, 2025.
  13. Cancer stat facts: Non-Hodgkin lymphoma. National Cancer Institute. https://seer.cancer.gov/statfacts/html/nhl.html. Accessed Oct. 1, 2025.
  14. Non-Hodgkin lymphoma treatment (PDQ) — Patient version. National Cancer Institute. https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq. Accessed Oct. 1, 2025.
  15. Elsevier Point of Care. Clinical Overview: Non-Hodgkin lymphoma. https://www.clinicalkey.com. Accessed Oct. 1, 2025.
  16. Cancer stat facts: NHL — Diffuse large B-cell lymphoma (DLBCL). National Cancer Institute. https://seer.cancer.gov/statfacts/html/dlbcl.html. Accessed Oct. 1, 2025.
  17. Cancer stat facts: NHL — Follicular lymphoma. National Cancer Institute. https://seer.cancer.gov/statfacts/html/follicular.html. Accessed Oct. 1, 2025.

相关

相关医疗程序

Mayo Clinic 新闻

产品与服务

非霍奇金淋巴瘤